137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S115-S116

  Lena, H ^a   Rizvi, N A ^b   Wolf, J ^c   Cappuzzo, F ^d   Zalcman, G ^e   Baas, P ^f   Mazieres, J ^g   Farsaci, B ^h   Blackwood Chirchir, M A ^h   Ramalingam, S ⁱ  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d ISTITUTO TOSCANO TUMORI   (Italy)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g SERVICE DE PNEUMOLOGIE   (France)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOCETAXEL; NIVOLUMAB;

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL LUNG CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 84982294020     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30247-7     Document Type: Article

References (0)